#news #biotech After COVID flop, Angion’s leading med fails again, this time in kidney transplant patients as shares halved

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: After COVID flop, Angion’s leading med fails again, this time in kidney transplant patients as shares halved .After COVID flop, Angion’s leading med fails again, this time in kidney transplant patients as shares halved
badams
Wed, 10/27/2021 – 04:48

from FierceBiotech: Biotech https://ift.tt/30WjMFI